Is Ultralife Corp. overvalued or undervalued?

As of 10 September 2025, the valuation grade for Ultralife Corp. has moved from attractive to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a P/E ratio of 30, an EV to EBIT of 22.38, and an EV to EBITDA of 15.03, all of which suggest a premium valuation compared to its peers.
In comparison, Allient, Inc. has a significantly higher P/E ratio of 128.16, while Solid Power, Inc. shows a negative P/E, indicating varying levels of financial health within the industry. Notably, Ultralife Corp. has underperformed against the S&P 500 over the past year, with a return of -23.88% compared to the index's 17.14%, reinforcing the notion that the stock may be overvalued at its current price.